A solid state form of Lumateperone ditosylate, selected from: a crystalline form of Lumateperone ditosylate designated form F1, characterized by data selected from one or more of the following: (i) an XRPD pattern having peaks at: 4.2, 6.3, 10.4, 14.6 and 18.7 degrees two theta ± 0.2 degrees two theta; and also by the absence of one, two, three or four peaks selected from: 11.4, 13.4,17.5 and 23.5 degrees two theta ± 0.2 degrees two theta, optionally substantially as depicted in Figure 2, or Figure 8 or Figure 9; (ii) an XRPD pattern having peaks at: 4.2, 6.3, 10.4, 14.6 and 18.7 degrees two theta ± 0.2 degrees two theta; and also by the absence of a peak at 5.7 degrees two theta ± 0.2 degrees two theta, optionally substantially as depicted in Figure 2, or Figure 8 or Figure 9: (iii) a solid state 13 C NMR spectrum having peaks at 142.6, 141.0, 133.8, 129.5 and 123.2 ppm ± 0.2 ppm and also by the absence of one, two three or four peaks selected from: 194.5, 110.2, 62.2 and 35.7 ppm ± 0.2 ppm, optionally substantially as depicted in Figure 4, 5 or 6: or a crystalline form of Lumateperone ditosylate designated form F1, wherein the form F1 contains: 20% or less, 10% or less, 5% or less, 2% or less, or 1% (w/w) or less of any other solid state forms of lumateperone tosylate or lumateperone ditosylate, which is characterized by data selected from one or more of the following: (i) an X-ray powder diffraction pattern having peaks at: 4.2, 6.3, 10.4, 14.6 and 18.7 degrees two theta ± 0.2 degrees two theta; (ii) an XRPD pattern having peaks at: 4.2, 6.3, 10.4, 14.6 and 18.7 degrees two theta ± 0.2 degrees two theta and also having one, two, three, four or five peaks selected from: 15.4, 20.4, 21.3, 24.0 and 25.1 degrees two theta ± 0.2 degrees two theta; (iii) a solid state 13 C NMR spectrum having peaks at 142.6, 141.0, 133.8, 129.5 and 123.2 ppm ± 0.2 ppm; and (iv) a solid state 13 C NMR spectrum having the following chemical shift absolute differences from a reference peak at 64.0 ppm ± 2 ppm of 78.6, 77.0, 69.8, 65.5 and 59.2 ppm ± 0.1 ppm. a crystalline form of Lumateperone ditosylate designated form F1, characterized by data selected from one or more of the following: (i) an XRPD pattern having peaks at: 4.2, 6.3, 10.4, 14.6 and 18.7 degrees two theta ± 0.2 degrees two theta; and also by the absence of one, two, three or four peaks selected from: 11.4, 13.4,17.5 and 23.5 degrees two theta ± 0.2 degrees two theta, optionally substantially as depicted in Figure 2, or Figure 8 or Figure 9; (ii) an XRPD pattern having peaks at: 4.2, 6.3, 10.4, 14.6 and 18.7 degrees two theta ± 0.2 degrees two theta; and also by the absence of a peak at 5.7 degrees two theta ± 0.2 degrees two theta, optionally substantially as depicted in Figure 2, or Figure 8 or Figure 9: (iii) a solid state 13 C NMR spectrum having peaks at 142.6, 141.0, 133.8, 129.5 and 123.2 ppm ± 0.2 ppm and also by the absence of one, two three or four peaks selected from: 194.5, 110.2, 62.2 and 35.7 ppm ± 0.2 ppm, optionally substantially as depicted in Figure 4, 5 or 6: or (i) an XRPD pattern having peaks at: 4.2, 6.3, 10.4, 14.6 and 18.7 degrees two theta ± 0.2 degrees two theta; and also by the absence of one, two, three or four peaks selected from: 11.4, 13.4,17.5 and 23.5 degrees two theta ± 0.2 degrees two theta, optionally substantially as depicted in Figure 2, or Figure 8 or Figure 9; (ii) an XRPD pattern having peaks at: 4.2, 6.3, 10.4, 14.6 and 18.7 degrees two theta ± 0.2 degrees two theta; and also by the absence of a peak at 5.7 degrees two theta ± 0.2 degrees two theta, optionally substantially as depicted in Figure 2, or Figure 8 or Figure 9: (iii) a solid state 13 C NMR spectrum having peaks at 142.6, 141.0, 133.8, 129.5 and 123.2 ppm ± 0.2 ppm and also by the absence of one, two three or four peaks selected from: 194.5, 110.2, 62.2 and 35.7 ppm ± 0.2 ppm, optionally substantially as depicted in Figure 4, 5 or 6: or a crystalline form of Lumateperone ditosylate designated form F1, wherein the form F1 contains: 20% or less, 10% or less, 5% or less, 2% or less, or 1% (w/w) or less of any other solid state forms of lumateperone tosylate or lumateperone ditosylate, which is characterized by data selected from one or more of the following: (i) an X-ray powder diffraction pattern having peaks at: 4.2, 6.3, 10.4, 14.6 and 18.7 degrees two theta ± 0.2 degrees two theta; (ii) an XRPD pattern having peaks at: 4.2, 6.3, 10.4, 14.6 and 18.7 degrees two theta ± 0.2 degrees two theta and also having one, two, three, four or five peaks selected from: 15.4, 20.4, 21.3, 24.0 and 25.1 degrees two theta ± 0.2 degrees two theta; (iii) a solid state 13 C NMR spectrum having peaks at 142.6, 141.0, 133.8, 129.5 and 123.2 ppm ± 0.2 ppm; and (iv) a solid state 13 C NMR spectrum having the following chemical shift absolute differences from a reference peak at 64.0 ppm ± 2 ppm of 78.6, 77.0, 69.8, 65.5 and 59.2 ppm ± 0.1 ppm. (i) an X-ray powder diffraction pattern having peaks at: 4.2, 6.3, 10.4, 14.6 and 18.7 degrees two theta ± 0.2 degrees two theta; (ii) an XRPD pattern having peaks at: 4.2, 6.3, 10.4, 14.6 and 18.7 degrees two theta ± 0.2 degrees two theta and also having one, two, three, four or five peaks selected from: 15.4, 20.4, 21.3, 24.0 and 25.1 degrees two theta ± 0.2 degrees two theta; (iii) a solid state 13 C NMR spectrum having peaks at 142.6, 141.0, 133.8, 129.5 and 123.2 ppm ± 0.2 ppm; and (iv) a solid state 13 C NMR spectrum having the following chemical shift absolute differences from a reference peak at 64.0 ppm ± 2 ppm of 78.6, 77.0, 69.8, 65.5 and 59.2 ppm ± 0.1 ppm.